GC Corp. and GC Cell Corp Acquire 1.43M Artiva Biotherapeutics Shares at $11.52

GC Corp. and its subsidiary GC Cell Corporation, both Korean companies, have acquired significant stakes in Artiva Biotherapeutics, Inc. (ARTV) through open market purchases. On May 11, 2026, GC Corp. directly purchased 1,085,069 shares at $11.52 per share, increasing its direct holdings to 4,391,969 shares. Simultaneously, GC Cell Corporation purchased 347,222 shares at the same price, bringing its indirect holdings to 1,607,734 shares. Both entities are ten percent owners of Artiva Biotherapeutics. The transactions represent a substantial investment totaling approximately $16.5 million. The filing includes detailed ownership disclosures noting that GC Corp. is ultimately controlled by its board of directors, who may be deemed to share voting and investment power over the shares held by both entities.